Linda Ortiz
Family · Robstown, TXNPI 1295752814
Payments from drug & device makers
Across 105 payments — averaging $37.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$831
- Dexcom, Inc.$382
- AbbVie$340
- Bayer$240
- Inspire Medical Systems, Inc.$179
- GSK$170
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,83698%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $831 |
| Dexcom, Inc. | 5 | $382 |
| AbbVie | 15 | $340 |
| Bayer | 6 | $240 |
| Inspire Medical Systems, Inc. | 2 | $179 |
| GSK | 4 | $170 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $140 |
| Si-bone, Inc. | 1 | $131 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $124 |
| Astellas Pharma US Inc | 3 | $121 |
| Corcept Therapeutics | 1 | $115 |
| Xeris Pharmaceuticals, Inc. | 6 | $113 |
| Melinta Therapeutics, LLC | 1 | $107 |
| Lilly USA, LLC | 6 | $104 |
| Esperion Therapeutics, Inc. | 2 | $99 |
| AstraZeneca | 5 | $92 |
| Medtronic | 1 | $81 |
| Nevro Corp. | 1 | $79 |
| Amgen | 5 | $78 |
| Boehringer Ingelheim | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Vertex | 1 | $22 |
| Exact Sciences | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$320
- DEXCOM G7 GSS (161)$238
- RYBELSUS$211
- iFuse Implant$131
- AJOVY$125
- NURTEC ODT$125
- UBRELVY$124
- QUVIVIQ$124
- DEXCOM STELO GLUCOSE BIOSENSOR$122
- Korlym$115
- DEXCOM G6 TRANSMITTER$114
- Saxenda$111
- Kimyrsa$107
- Kerendia$100
How this compares
$3,921 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $104,738 |
| TradjentaLinagliptin | 69 | $55,208 |
| RybelsusSemaglutide | 26 | $51,047 |
| JanuviaSitagliptin Phosphate | 38 | $38,294 |
| MyrbetriqMirabegron | 36 | $33,863 |
| TrulicityDulaglutide | 21 | $28,027 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $25,609 |
| EliquisApixaban | 40 | $24,332 |
| MounjaroTirzepatide | 20 | $24,275 |
| XareltoRivaroxaban | 12 | $11,489 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,489 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $10,407 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $10,372 |
| Levemir FlexpenInsulin Detemir | 21 | $7,950 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $831 | $155,78698 claims |
| Boehringer IngelheimTradjenta, Combivent Respimat | $46 | $61,58382 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $104 | $52,30241 claims |
| Astellas Pharma US IncMyrbetriq | $121 | $33,86336 claims |
| PfizerEliquis | $19 | $24,33240 claims |
| AstraZenecaSymbicort | $92 | $10,37242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Robstown
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.